|
KMID : 1011820200610010067
|
|
Investigative and Clinical Urology
2020 Volume.61 No. 1 p.67 ~ p.74
|
|
|
Effect of 5α-reductase inhibitors on the efficiency of thulium:yttrium-aluminium-garnet (RevoLix®) vaporesection for treating benign prostatic hyperplasia
|
|
Chung Jae-Seung
Seo Won-Ik
Oh Cheol-Kyu
Kim Seong-Cheol
Park Myung-Chan
Park Sang-Hyun
Yu Ji-Hyeong
Lee Chan-Ho
Kim Wan-Suk
Park Tae-Yong
Min Kweon-Sik
Chung Jae-Il
|
|
|
Abstract
|
|
|
Purpose: Preoperative use of 5α-reductase inhibitors (5ARIs) may cause fibrosis of the prostate tissue and reduce the efficiency of thulium laser surgery for treating benign prostate hyperplasia (BPH). Thus, we investigated the effects of preoperative 5ARI use in this setting.
Materials and Methods: This retrospective study examined 184 patients who underwent thulium laser surgery for BPH during 2012?2017. Patients were grouped according to their 5ARI use in order to compare their preoperative and intraoperative characteristics and subsequent outcomes. Surgical efficiency was assessed using vaporesection efficiency. The total operation time, vaporesection time and prostate volume change were measured.
Results: The 5ARI+ group included 83 patients (45.1%) and the 5ARI? group included 101 patients (54.9%). There were no significant differences in the two groups' preoperative characteristics, postoperative prostate size, thulium laser energy use, or prostate volume reduction rate. However, relative to the 5ARI? group, the 5ARI+ group had a significant shorter total operative time (65.0 min vs. 70.0 min, p=0.013) and a significantly shorter vaporesection time (48.0 min vs. 54.0 min, p=0.014), which resulted in significantly higher vaporesection efficiency in the 5ARI+ group (0.66 mL/min vs. 0.51 mL/min, p<0.001). Both groups exhibit significant improvements in their quality of life score and International Prostate Symptom Score during the 12-month follow-up.
Conclusions: In contrast with our expectations, the preoperative use of 5ARI increased the efficiency of thulium laser surgery for BPH. Thus, it may not be necessary to stop 5ARI treatment before performing thulium laser surgery in this setting.
|
|
|
KEYWORD
|
|
|
Laser therapy, Prostatic hyperplasia, Thulium, 5-alpha reductase inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|